AACR commits to Love/Avon Army of Women

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

The American Association for Cancer Research will provide scientific expertise to Love/Avon Army of Women, an organization that seeks to link more than one million women volunteers with cancer researchers across the country to discover breast cancer causes and to aid in prevention.

The American Association for Cancer Research will provide scientific expertise to Love/Avon Army of Women, an organization that seeks to link more than one million women volunteers with cancer researchers across the country to discover breast cancer causes and to aid in prevention.

AACR member physicians and scientists working in the field of breast cancer research will occupy eight seats on the scientific advisory committee and one seat on the steering committee. The AACR will assist in decision making regarding the policies, direction, and vision of the project as well as in the review of requests from scientists seeking permission to solicit volunteers from the Love/Avon Army of Women for their breast cancer research studies.

Only investigators who have a peer-reviewed study will gain access to volunteers in the Love/Avon Army of Women. Each study will undergo a thorough scientific, safety and ethical review by expert scientists.

The AACR will use its major scientific meetings and its journal Cancer Prevention Research as forums to present the research.

Women interested in participating in this effort may enroll at www.armyofwomen.org. Healthy women of every age and ethnicity are eligible.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content